NVCT Expands Portfolio
Nuvectis announces strategic portfolio expansion via license agreement with Haisco Pharmaceutical Group for two clinical-stage compounds
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.